Lush demonstrates what an Internet shutdown might look like, before resolving to this page. Howard Lake | 26 November 2016 | News Lush Charity PotLush supports other causes and groups from profits from sales of some of its products. In particular The Lush Charity Pot scheme supports local and global organisations fighting for human rights. 216 total views, 2 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis28 Anyone purchasing the bath bomb from Lush’s website will encounter a intervening page that mimics an Internet shutdown on the device, which then resolves into an explanation of the #KeepItOn campaign. They can choose to proceed to the Lush page or to sign Access Now’s petition to world leaders. In 2012 we covered The power of the 404 page to help missing children.The 404 page has featured in most of our digital fundraising training courses over the past 20 years. Access Now has documented over 50 internet shutdowns in 2016 alone, “and the number is only increasing”. The organisation and Lush chose Black Friday (25 November) to launch the global #KeepItOn campaign against internet shutdowns together with a limited edition Error 404 bath bomb. Handmade cosmetics brand Lush has introduced Error 404, “a bath bomb with a difference”. Sales of the fizzy fragrant product will help organisations fight against government-enforced internet shutdowns.All profits from the sale of the Error 404 bath bomb will be donated by Lush to a global Digital Fund that supports the work of charity Access Now and other grassroots organisations working in the field of digital rights. The total fundraising target for the Digital Fund is £250,000.Lush is selling the product appropriately enough for £4.04.The product is hand-made from 13 ingredients including vanilla extract, gardenia extract, antique gold lustre, citric acid and glacier blue lustre. It should be dropped into the bath, where its gold exterior will fizz away, revealing a blue pool “with a secret message”.[youtube]https://www.youtube.com/watch?v=y7C-ZoOh5mc[/youtube] Digital FundImage: Lush LtdThe Digital Fund will offer grants from £100 to £10,000 to grassroots activists and charities protecting freedom of expression in the digital era.The application process will start on 7 December 2016, and the deadline for completed applications to be submitted is 15 January 2017.Applications are accepted from anywhere in the world. Smaller organisations will be given priority, “particularly those hoping to create long-term change through education, advocacy and campaigning, or those tackling the root cause of the problem”. Lush’s Error 404 bath bomb to help fund #KeepItOn digital rights campaign Tagged with: corporate 215 total views, 1 views today About Howard Lake Howard Lake is a digital fundraising entrepreneur. Publisher of UK Fundraising, the world’s first web resource for professional fundraisers, since 1994. Trainer and consultant in digital fundraising. Founder of Fundraising Camp and co-founder of GoodJobs.org.uk. Researching massive growth in giving. Error 404 and #KeepItOnError 404 is the standard HTTP code for indicating a “page not found” on web servers. It is the kind of page that users might see if their government shut down the Internet in their country.According to Access Now:“An internet shutdown happens when someone— usually a government — intentionally disrupts the internet or mobile apps to control what people say or do. Shutdowns are also sometimes called “blackouts” or “kill switches”.” Advertisement AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis28
Finnish mutual pension insurance company Etera has refuted claims it may merge with another Finnish mutual pension insurance company next year.In a statement, the company’s managing director Hannu Tarkkonen said Etera would continue as an independent pension insurance company, despite speculation in the Finnish media to the contrary.Helsingin Sanomat, the largest daily in Finland, reported last week that Etera’s returns and solvency had weakened so markedly over the year to date that it considered solving the situation by merging with Ilmarinen, the second largest mutual pension insurance company in Finland.Allegedly, Fennia Pension and LocalTapiola Pension, which will merge at the end of 2013, had also been interested in merging with Etera. In addition, according to the newspaper, the management fees Etera charges from its customers are insufficient to cover all its operational costs.The newspaper said the firm would, therefore, have to fill in the gap from its investment returns.According to Helsingin Sanomat, Finland’s Financial Supervisory Authority (Fiva) is observing the situation, which many pension professionals consider extremely problematic.Etera currently manages assets worth nearly €5.6bn, and generated a -0.4% return for its investments over the first three quarters of 2013.Ilmarinen manages assets worth nearly €31.5bn, while its investments returned 6.5% over the same period.Etera’s solvency level, 16.2%, is currently the weakest among Finnish mutual pension insurance companies.Ilmarinen’s solvency level stood at 25.8% after the third quarter of this year.The core of Etera’s investment strategy is to diversify risks as much as possible, which has not worked in this year’s market environment, Tarkkonen said.“We were actually prepared for weaker development of the markets,” he said.“Equity markets developed better than we expected because of the actions central banks took.”According to him, although Etera’s solvency level has fallen this year, it is still within the “normal” operational range.Tarkkonen, who will retire next summer added: “The situation [still] enables having normal, full-scale investment operations.”
Nine-year-old Sammy and four-year-old Msizi are tuberculosis patients at Lifecare Knights hospital in Germiston. The Southern African region has the highest incidence of the disease in the world. (Image: World Lung Foundation)Janine ErasmusKwaZulu-Natal University and the Howard Hughes Medical Institute have joined to establish the KwaZulu-Natal Research Institute for Tuberculosis and HIV, a research centre of international standard that will focus on contributing meaningfully to the global fight against tuberculosis (TB) and HIV.The two diseases often go hand in hand, as TB is increasingly seen as an opportunistic disease that takes advantage of HIV sufferers’ weakened immune system to entrench itself. While an opportunistic disease usually only appears when the immune system is compromised, TB is now seen as such a disease in those infected with the Aids virus.According to the World Health Organisation the disease is the leading infectious killer of people living with HIV and in fact, the two are so closely connected that the term “co-epidemic” or “dual epidemic” is often used to describe their relationship.In South Africa the dual epidemic is especially virulent, as the country has the highest number of HIV-positive people in the world. Many sufferers contract the extreme drug-resistant strain of TB, which was first noticed in Tugela Ferry in 2005. In the rural KwaZulu-Natal town, 44 people contracted the deadly TB strain – all were found to be HIV positive, and all but one of them died.International centre of research excellenceHowever, there is now fresh cause for hope. The KwaZulu-Natal research institute, which has been two years in the planning, was announced simultaneously in Washington, DC, and Durban on 19 March 2009.As part of its goal of becoming an international centre of research excellence, the institute will also concentrate its efforts on producing a new generation of research scientists that, with training in the field, will be able to competently tackle African issues.The facility will be housed in a brand-new six-floor state-of-the-art BSL-3 laboratory on the campus of the Nelson Mandela School of Medicine in Durban. A BSL-x classification refers to the biosafety level of a facility, and level three applies to those facilities, whether they are of a diagnostic, teaching, research, or production nature, that work with indigenous pathogens capable of causing serious or potentially lethal disease after inhalation.Construction of the building is expected to begin in September 2009.Supporting medical researchThe non-profit Howard Hughes Medical Institute (HHMI), established in the 1953 by the late aviation magnate Howard Hughes, is one of the largest private funding organisations for biological and medical research in the US.After the Bill and Melinda Gates Foundation, the institute is the second-wealthiest philanthropic organisation in the US with an endowment of a staggering R180.7-billion (US$18.6-billion). It is also the second-best endowed medical research foundation in the world, coming in behind the UK’s Wellcome Trust.The HHMI will invest committed R583-million ($60-million) into the KwaZulu-Natal initiative over the next decade, providing R29-million ($3-million) in grant funding and for the construction of temporary laboratory facilities in 2009.Outgoing president of the HHMI, Thomas Cech, said that it was the joint view of the HHMI and the university that substantial investment into research in the heart of the pandemics of HIV and TB will yield major discoveries, and do much to alleviate the suffering caused by these diseases.“There is no better place on the continent to conduct research into TB,” said Professor Malegapuru Makgoba, vice-chancellor of KwaZulu-Natal University. “The partnership is addressing a real problem that affects real people.”According to Robert Tjian, the incoming president of the HHMI, the project will have global benefits. “This initiative is one of the most challenging we have embarked upon in our international programme,” he said. “I look forward to seeing how the facility realises the potential for developing new strategies to combat the dual scourge of HIV and tuberculosis – both for South Africa and the entire world.”The South African institute will focus initially on four core research areas – development of rapid and more effective tests for TB, research into the characteristics of drug resistant strains of TB, analysis of the complex immune response to TB, specifically among those already infected with HIV, and a study of recurrent TB in HIV-positive patients to assess the nature of the recurrence.Do you have queries or comments about this article? Email Janine Erasmus at [email protected] articlesIncentive scheme for the poorMobile HIV testing in KZN TB diagnosis breakthroughBig medicine from a little plant Alive & Kicking up a storm Useful linksHoward Hughes Medical InstituteKwaZulu-Natal UniversityHIV statistics – South AfricaWorld Health Organisation – TB and HIVWorld Health Organisation – South Africa
Prof Kelly Chibale (centre front) and his team have brought the world closer than ever before towards finding a cure for malaria.(Image: H3-D) The female Anopheles mosquito picks up the disease when she drinks the blood of an infected person and transmits it when she moves to the next person..(Image: Centres for Disease Control)MEDIA CONTACTS • Elaine Rutherfoord-JonesAdministrator, H3-D Drug Discovery andDevelopment Centre+27 21 650 5495Lorraine KearneyA malaria-free world: this is a tantalising possibility that may be now within our grasp. And it’s a proudly South African project, says Prof Kelly Chibale, the director and executive committee member of the Drug Discovery and Development Centre (H3-D) at the University of Cape Town (UCT).Last week, flanked by the professor, Science and Technology Minister Naledi Pandor announced the discovery at the centre of a potential single oral dose cure for malaria, the holy grail in lightening the world’s disease burden.Chibale, who is the lead researcher of the collaborative research project, explains: “This is a potential cure for malaria. It is now entering the clinical trial phase – clinical trials should begin at the end of 2013. If the trials are successful, then not only will we have a cure for malaria, but it will also have the potential to stop person-to-person transmission of the parasite.”The breakthrough is huge: at stake is the possibility of eradicating malaria at some stage in the future, he stresses.“With this molecule, we have a potential drug that works at all life cycle stages of the parasite, including at the blood stage, and at the stage where transmission back to the mosquito occurs.”Essentially, this means that it would stop the parasite from infecting mosquitoes when they bite people who have malaria.Work started on the discovery back in early 2008, in Geneva, Switzerland. Dr Tim Wells, the chief scientific officer at the Medicines for Malaria Venture (MMV) was about to start a campaign to test chemical samples to find new compounds that would act against the human malaria caused by the Plasmodium falciparum parasite. He was working with Prof Vicky Avery at the Eskitis Institute at Griffiths University in Brisbane, Australia.The H3-D was set up in April 2010 through the joint efforts of MMV, UCT and other international stakeholders, as well as the South African government. They included Cape Biotech Trust, which is now part of the Technology Innovation Agency.The project that led to the discovery of MMV390048 in September 2010 began on 1 April 2009, and became a purely South African venture in January 2012.Professor Chibale explains that the discovery, which happened at UCT, was particularly significant because it was the first-ever clinical molecule discovered by Africans. It will be the first clinical candidate researched in Africa.How malaria worksOnce a person is bitten by a carrier mosquito and is infected, the parasite attacks the person’s liver. Malaria is transmitted by mosquitoes of the Anopheles genus, and in Africa the culprit is the A. gambiae complex of seven indistinguishable insects.At this stage, there are no symptoms of the disease. It multiplies rapidly in the liver and invades the blood, causing red blood cells to explode. Debilitating sickness sets in, often leading to death, particularly among children. But the MMV390048 molecule could also potentially work as a prophylaxis, Chibale points out.Taken before you entered a malaria area, it could prevent the parasite from multiplying if you were bitten. And for those people who lived in malaria areas, who can have several episodes of the disease a year, it could protect them from reinfection.The potential cure can make other claims: it works on all strains of the disease, including that found in Africa, which is mostly from P. falciparum, the most deadly, and that found in Asia, mostly from P. vivax, which is responsible for relapse. And it works on drug-resistant strains of malaria. But perhaps most importantly, it is a potential cure.“Our definition of a cure is that after 30 days there is not a single parasite in a sample from a live animal. Chloroquine, one of the drugs used now to treat malaria, does not cure in the same animal model; there are still some parasites in the blood of animals treated with chloroquine 30 days after treatment,” the professor explains.“This is very exciting. It is a single dose, while other drugs need high multiple doses in the same animal model. This has huge cost and compliance [medicine adherence] implications. People often take a drug, feel better and stop taking the medication. But they still have the parasite in their systems. This leads to drug-resistance. This molecule could stop this.”Cost is a big issue. “We want it to be a single oral dose costing less than a dollar per treatment. This was one of the issues we identified in the lead optimisation phase of development.”The molecule is synthetic, from the aminopyridine class, helping to keep costs down. It is made in the laboratory from readily available resources. Supply issues are very important in drug manufacture, and this molecule can be made in a few steps, which makes it cheaper, Chibale stresses.“During the crucial lead optimisation phase, we tested for cardiotoxicity and drug-drug interaction risks. Then, the penultimate phase was the candidate profiling stage, when we gathered data, mostly on safety – because the safety of future patients is the most important thing. Once we had a dossier, we presented it to Medicines for Malaria Venture’s expert scientific advisory committee in July. They approved the molecule for clinical development.”MMV’s funders include BHP Billiton and Exxon Mobile.Clinical trials nextThe next step, now being taken, is preparing for clinical trials: patients and volunteers need to be recruited and permission needs to be granted by the authorities. A commercial venture also needs to be found to manufacture the drug at scale.“This is being discussed now. The idea is to do as much as possible in South Africa.”Developing the molecule has been a steep but worthwhile learning curve for the scientists at UCT.“We have no guarantee on the clinical trials,” Chibale says. “But we have so many positive spin-offs so far. We’ve been able to develop skills and expertise. Lessons have been learned. And the skills are now being used for other illnesses. Now we know how to discover drugs – it is not only a gift to Africa, but a gift to the world.“It also provides employment, such as in manufacturing. And we now have back-ups. We have a healthy pipeline to keep discovering and making useful drugs. Because it is a continuous war against the organisms. They want to live, and they are very clever, so we need to keep finding new ways to beat them, because we want to live too.”Funding for the project came from the Department of Science and Technology, which invested R25-million (US$3-million). Chibale also has a research chair from the department. MMV invested about R15-million ($1.8-million), and UCT provided the infrastructure and some funding. A partnership has also been set up between MMV and the department’s Technology Innovation Agency, and the project is now being funded by the two entities on a one for one basis. It has been scaled up with this new funding, and the team has been able to expand from four to 10 scientists.If MMV390048 indeed proves to be a cure, the implications will be far-reaching. Malaria plays a big role in the cycle of poverty, Chibale points out. It debilitates its victims; they cannot work and take weeks to recover. Without proper nutrition and the ever-present possibility of reinfection, the disease’s toll is massive in human terms and on productivity.A child dies every 46 seconds from malaria in sub-Saharan Africa, and 90% of malaria deaths take place in sub-Saharan Africa, Dr Tom Ellman, head of Medecins Sans Frontieres South African Medical Unit, was quoted as saying in the Daily Maverick. It was estimated that African economies lost up to R100.5-billion ($12-billion) a year directly related to malaria and its impact on productivity.Malaria fact sheetThe World Malaria Report 2011 issued by the World Health Organisation in December 2011 reported:There were 216 million cases of malaria in 2010; 81% of these were in the WHO African Region.An estimated 3.3 billion people were at risk of malaria in 2010.An estimated 655 000 people died of malaria in 2010; 86% of the victims were children under 5 and 91% of malaria deaths occurred in the WHO African Region.In 2010, there were 46 malaria-endemic countries in sub-Saharan Africa; 43 of these belong to the WHO African Region, and three (Sudan, Somalia and Djibouti) were in the WHO Eastern Mediterranean Region.45 countries around the world have identified resistance to at least one of the four classes of insecticides used for malaria vector control; 27 of these are in sub-Saharan Africa.Estimated malaria cases and deaths by WHO Region, 2010Region Estimated cases Estimated deathsAfrican Region 174-million 596 000Americas Region 1-million 1 000Eastern Mediterranean Region 10-million 15 000European Region 20 0South-East Asia Region 28-million 38 000Western Pacific Region 2-million 5 000
Learners in impoverished schools in the Western Cape have received educational resources thanks to the Rally to Read initiative.(Image: Rally To Read)Brand South Africa once again combined efforts with Bidvest Rally to Read to contribute to the improvement of literacy and education in South Africa.Rally to Read aims to help improve education in rural South Africa, and the partnership is in line with Brand South Africa’s aim of a South Africa with quality school education that has literacy and numeracy at globally competitive standards.Rally to Read is an initiative that was originally launched by the McCarthy Motor Group and is now organised by Bidvest.Every year, Rally to Read travels across 10 school districts in all nine provinces to distribute reading and educational resources to disadvantaged schools.On Saturday, 21 October 2017, Brand South Africa collaborated with the teams to play their part in Noordhoek and Paternoster in the Western Cape.Brand South Africa also recognised the teachers for their hard work towards improving education.Visit Rally To Read for more information. Would you like to use this article in your publication or on your website? See Using Brand South Africa material.
Former Real Madrid midfielder Christian Karembeu believes that his former club are the clear favourites to retain their Champions League title for a third consecutive seasonZinedine Zidane’s side have had a rather humbling domestic season, after their success last season, with Real currently 15 points behind Barcelona in La Liga and they were left stunned when Leganes knocked them out of the quarter-finals of the Copa del Rey.But Karembeu, who won the Champions League twice in his time at the club, is confident that they can win the competition this season against the likes of Barcelona, Manchester City and Bayern Munich.“Don’t even ask the question,” the former Madrid midfielder told Omnisport, according to SportsKeeda.“Only Real can win it [the Champions League], that’s it.“In Kiev, who’s going to play against Real, this I don’t know. Real will be in Kiev however, yes.”Opinion: Neymar will earn respect back from the PSG fans Tomás Pavel Ibarra Meda – September 14, 2019 After completing his incredible return to Parc des Princes, we predict that Neymar will earn the respect back from PSG supporters.The situation between Neymar…Karembeu also voiced his support for Zidane and is full of optimism about his potential at the Santiago Bernabeu: “He [Zidane] was an amazing player and he will become an amazing coach,” he added. “He’s doing it already.”The former French international is also backing Didier Deschamps to lead France to glory in the World Cup: “France will win because 20 years ago we did it,” he added. “Didier Deschamps is experienced and knows his group.“They played a final of a European Championship at home.“He saw some interesting performances. It was a successful competition. He has to bounce back.”Karembeu spent three season at Real from between 1997 and 2000. As well as winning the Champions League twice, the now 47 year-old also won the Intercontinental Cup in 1998.
West Ham United are facing tough times in trying to secure a long-term future for the young player of the year Declan Rice after he rejected an improved contract offer they tabled.However, West Ham are self-assured that teenage defender Declan Rice will still stay at the club even after his new agents WMG have turned down the club’s opening proposal, according to Standard Uk.The 19-year-old current deal will end in 2020 and is worth £3,000 a week. The new offer would see that figure rise to £8,000.Rice became a first-team regular in the last season as a result of injuries. The Republic of Ireland international star turned down West Ham’s initial offer which has stimulated interest from potential suitors.Rice tips Mount for greater things Taimoor Khan – September 11, 2019 Declan Rice says that Mason Mount is going to match the exploits of Frank Lampard when he was in his prime during his playing…They are just beginning to go into talks about the defender’s future as West Ham look set to return with a better offer.Rice made 31 senior appearances last season, including 26 in the Premier League, and also made his senior international debut for the Republic of Ireland.Also, Scotland midfield player Robert Snodgrass will return to West Ham when they start pre-season training next month, following the end of his loan spell at Aston Villa.
Arsenal and Tottenham have appealed to fans to be on their best behaviour in Wednesday night’s Carabao Cup tie. after a racist abuse marred the last encounter.Arsenal ran away 4-2 winners in the last encounter earlier this month but it made headlines for the wrong reasons when a Spurs fan threw a banana onto the pitch as Pierre-Emerick Aubameyang celebrated scoring a goal.A Tottenham supporter has been fined and handed a four-year football banning order after pleading guilty to throwing a missile and both sides are keen to avoid a repeat of any such unsavoury incidents for the Carabao Cup quarter-final clash.“Local derby matches are always passionate affairs and it is important that supporters play their part on these occasions by getting behind the team in a positive way and making them memorable for the right reasons,” Tottenham said on their official website.A message to all supporters attending tonight’s Carabao Cup quarter-final against Arsenal.— Tottenham Hotspur (@SpursOfficial) December 19, 2018Pochettino admits Wanyama remains in his Spurs plans Manuel R. Medina – September 14, 2019 Kenyan international, Victor Wanyama, was the protagonist of a summer transfer saga, but in the end, he is set to stay at Tottenham Hotspur.“We have enjoyed some unforgettable north London derby encounters over the years and the vast majority of fans have generated incredible atmospheres on these occasions.“However, there were incidents in our most recent Premier League fixture against Arsenal earlier this month where a small number of supporters of both sides behaved unacceptably.“Ahead of Wednesday’s Carabao Cup quarter-final tie, we wish to remind supporters travelling to Emirates Stadium that any kind of racist, discriminatory or anti-social behaviour will not be tolerated by the club.“As a club that has suffered from abuse in the past from opposition supporters, we wish to make clear that there is absolutely no place for this kind of behaviour in or outside of football.”